Despite evidence of high heritability, monogenic disorders are identified in a minor fraction of individuals with early-onset coronary artery disease (EOCAD). We hypothesized that some individuals with EOCAD carry a high number of common genetic risk variants, with a combined effect similar to Mendelian forms of coronary artery disease, such as familial hypercholesterolemia.
METHODS AND RESULTS:
To confirm the polygenic contribution to EOCAD (age of ≤40 years for men and ≤45 years for women), we calculated in 111 418 British participants from the UK Biobank cohort a genetic risk score (GRS) based on the presence of 182 independent variants associated with coronary artery disease (GRS182). Participants with a diagnosis of EOCAD who underwent a revascularization procedure (n=96) had a significantly higher GRS182 (P=3.21×10 −9 ) than those without EOCAD. An increase of 1 SD in GRS182 corresponded to an odds ratio of 1.84 (1.52-2.24) for EOCAD. The prevalence of a polygenic contribution that increased EOCAD risk similar to what is observed in heterozygous familial hypercholesterolemia was estimated at 1 in 53. In a local cohort of individuals with EOCAD (n=30), GRS182 was significantly increased compared with UK Biobank controls (P=0.001). Seven participants (23%) had a GRS182 corresponding to an estimated 2-fold increase in EOCAD risk; none had a rare mutation involved in monogenic dyslipidemia or EOCAD.
CONCLUSIONS:
These results suggest a significant polygenic contribution in individuals presenting with EOCAD, which could be more prevalent than familial hypercholesterolemia. Determination of the polygenic risk component could be included in the diagnostic workup of patients with EOCAD. C oronary artery disease (CAD) is a leading cause of mortality worldwide and has a tremendous effect on the life of an individual and his family, particularly when occurring at an early age. Except for a few rare Mendelian disorders, the origin of CAD in young individuals remains poorly explained, despite evidence that heritability is as high as 60%. 1 In a recent genome-wide association study metaanalysis, common single-nucleotide polymorphisms (SNPs; allele frequency >1%) at 56 loci were found to be associated with CAD (additive model) at genomewide significance level, and 202 variants have shown suggestive association (false discovery rate of 5%), together explaining ≈20% to 25% of CAD heritability. 2 Although some of those variants are associated with known risk factors, such as lipids and blood pressure, the mechanism by which most of them increase CAD risk remains unknown. Several studies have looked at the predictive ability of genetic risk scores (GRSs) that sum the burden of risk associated with a combination of these variants. It has been suggested that an increase in GRSs is associated with earlier manifestation of CAD. 3, 4 Therefore, it is plausible that a markedly increased GRS could contribute to the manifestation of early-onset CAD (EOCAD), by a magnitude comparable with Mendelian forms of CAD, such as familial hypercholesterolemia (FH).
We hypothesized that there would be a significant polygenic contribution in individuals presenting with EOCAD and that some would have a score leading to a significant increase in risk (ie, >2-fold). We first show the increase in GRS observed in individuals with EOCAD in the UK Biobank cohort and report several cases of EOCAD from a local cohort with a substantial polygenic contribution.
METHODS

Study Population and Genetic Data
UK Biobank
UK Biobank is a large prospective cohort of ≈500 000 individuals between 40 and 69 years of age recruited from 2006 to 2010 in several centers located in the United Kingdom. 5 The present analyses were conducted under UK Biobank data application number 15 255. We used genotyping data obtained from the first genetic data release, including 152 249 individuals. Samples were genotyped with the Affymetrix UK Biobank Lung Exome Variant Evaluation (UK BiLEVE) Axiom array or the Affymetrix UK Biobank Axiom Array. Phasing and imputation were performed centrally using a reference panel combining UK10k and 1000 Genomes Phase 3 samples. Samples from the UK Biobank genomic analysis exclusions, related samples, samples with call rate <99%, sex mismatch, nonwhite British ancestry, and quality control failure in the UK BiLEVE study were excluded. For analysis, 111 418 samples remained. Variants with call rate <95%, Hardy-Weinberg equilibrium P<10 -6 , or with imputation quality score <0.3 were excluded. Operative codes 4 were used to identify participants with documented obstructive CAD, which was defined as coronary artery bypass grafting (CABG) or coronary angioplasty±stenting (K40.1-40.4, K41.1-41.4, K45.1-45.5, K49.1-49.2, K49.8-49.9, K50.2, K75.1-75.4, and K75.8-75.9). The EOCAD group consists of individuals with documented obstructive CAD and self-reported myocardial infarction or angina at ≤40 years of age for men and ≤45 years of age for women. Participants who did not meet these criteria were assigned to the control group (including participants with later-onset documented obstructive CAD when comparing with the EOCAD group).
Local Cohort
Participants were recruited at the Hamilton Health Sciences Heart Investigation Unit between February 2014 and April 2016. All individuals with angiography proven significant obstructive CAD (>70% stenosis in at least 1 major epicardial vessel) at ≤40 years of age for men and ≤45 years of age for
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women were approached for participation in the study (n=42 ), HIV, chronic hepatitis, chronic inflammatory disease, use of corticosteroids, or known consumption of cocaine or amphetamine were considered as having a potential secondary cause of CAD and were, therefore, not eligible for participation in the study. We also excluded individuals of non-European descent (n=12), based on questionnaire and genetic principal component analysis because the GRS is based on variants and effect sizes derived from a mainly European population. The study complies with the Declaration of Helsinki and was approved by the Hamilton Integrated Research Ethics Board. All participants provided written informed consent.
Samples were genotyped using the HumanCoreExome BeadChip (Illumina, Inc, San Diego). Quality control procedures were performed using PLINK software, version 1.07. 6 Samples with call rate <95%, sex mismatch, non-white ancestry, and related samples were excluded. Variants with call rate <95%, Hardy-Weinberg equilibrium P<10 -6 , or minor allele frequency <0.01 were excluded. After phasing the data using SHAPEIT, version 2, 7 imputation was performed using IMPUTE, version 2.3.2, 8 with a reference panel based on 1000 Genomes Project phase I integrated variant set v3 (June 2014 release) in NCBI Build 37 (hg19) coordinates. After imputation, SNPs with imputation certainty (info score) <0.3 were excluded.
Whole-exome sequencing was performed in all participants in the local cohort using the Ion Proton and Ion S5XL platforms (Life Technologies). Samples were sequenced to a mean depth of 86.8×, and 86.3% of target bases were covered by at least 20 sequence reads. Single-nucleotide variants, insertions, and deletions were called with version 5.2 of the Torrent Variant Caller (Life Technologies). Variants altering protein structure with minor allele frequency <5% according to version 0.3 of the Exome Aggregation Consortium 9 and an in-house data set located in 31 genes known to cause monogenic dyslipidemia or EOCAD (Table I in the Data Supplement) 1,10 were further evaluated using the ClinVar database 11 and InterVar software. 12 Variants identified as potentially disease-causing were confirmed with Sanger sequencing.
Statistical Analysis
We calculated weighted GRSs based on data from the latest Coronary Artery DIsease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics (CARDIoGRAMplusC4D) Consortium meta-analysis, 2 using SNPs associated with CAD at a 5% false discovery rate (n=202). We removed SNPs in linkage disequilibrium with an r 2 >0.2 in 1000 Genomes Project phase 1 v3 training set European population (n=379 individuals). For each pair of SNPs in linkage disequilibrium, the SNP with the higher P value was removed (n=6). Among the remaining SNPs, 182 could be retrieved from the UK Biobank data, which were combined to calculate the final score (GRS182; Table II in the Data Supplement). Among these SNPs, 47 (25.8%) were previously associated with a traditional CAD risk factor (BMI, waist-to-hip ratio, lipids, blood pressure, and type 2 diabetes mellitus) in genome-wide association study meta-analyses [13] [14] [15] [16] [17] [18] ( Table II in the Data Supplement). GRS182 was calculated by summing, for each SNP, the number of risk alleles weighted by the log of the odds ratio (OR) observed in the recent CARDIoGRAMplusC4D Consortium meta-analysis. 2 Allele dosage was used for the imputed data (fractional value between 0 and 2) to account for imputation uncertainty. Of note, UK Biobank participants were not part of the CARDIoGRAMplusC4D Consortium meta-analysis.
Mean GRS182 was compared between individuals with EOCAD (first in UK Biobank and then in the local cohort) and individuals without EOCAD from UK Biobank using Student t test.
GRS182 was also compared with a distribution generated from the expected allele frequencies in a general white population. Allele frequencies were retrieved from the Haplotype Reference Consortium (HRC) release 1.1 (http:// www.haplotype-reference-consortium.org/), which is based on >30 000 samples mostly of white ancestry; we used allele frequencies calculated after excluding 1000 Genomes Project data (because it included a high proportion of samples from non-white ancestries). When unavailable in HRC, we used the allele frequency from 1000 Genomes phase 1 v3 training set European population (n=379).
Enrichment for high GRS182 in the local cohort was evaluated with Fisher combined probability test first using the estimated percentile in the UK Biobank cohort and then using the general white population (calculated from allele frequencies as stated above).
Logistic regression was performed to evaluate the association between GRS182 and the presence of EOCAD in the UK Biobank cohort, before and after adjustment for clinical risk factors: age, sex, BMI, waist-to-hip ratio, smoking, hypertension, diabetes mellitus, and first-degree family history of heart disease (lipid levels were not available). The OR for an increase of 1 SD in the score was obtained by calculating the natural exponential function of the regression coefficient scaled to correspond to 1 SD. Trend was verified by calculating observed OR for EOCAD by quartiles of GRS182 in the UK Biobank cohort. Significance was evaluated with χ 2 test for trend (also called Cochran-Armitage test for trend). The same analysis was performed with all documented obstructive CAD (using operative codes 4), regardless of age of onset, as the outcome.
To test the hypothesis that individuals without EOCAD and with a high GRS182 have lower traditional risk factors (for example, by adhering to a healthier lifestyle), we compared the clinical characteristics of individuals without EOCAD in UK Biobank based on their GRS182, using a threshold that increased EOCAD 2-fold. We performed a similar analysis in individuals with EOCAD.
ORs for the local cohort were first calculated based on the regression coefficient observed for EOCAD and CAD in the UK Biobank cohort with 95% confidence intervals evaluated from standard errors. ORs for the risk of CAD were also calculated based on the effect sizes reported in the CARDIoGRAMplusC4D Consortium meta-analysis. For each participant, GRS182 was compared with the mean GRS182 in the expected distribution in the general white population. Based on 100 000 simulations, 95% confidence intervals were calculated with bootstrapping taking into account the uncertainties of the log of the ORs (based on reported standard errors) and allele frequencies.
P values <0.05 were considered significant. Statistical analyses were performed using R (version 3.2.2) unless stated otherwise.
RESULTS
Clinical Characteristics
Ninety-six individuals from the UK Biobank cohort had EOCAD (77 men and 19 women), and 111 283 individuals were included in the control group (47% men; median age of 58 years).
Thirty individuals with EOCAD without evidence of a secondary cause (20 men and 10 women) were included in the local cohort (Table III in the Data Supplement) . The majority presented with ST-segment-elevation myocardial infarction (56.7%) or non-ST-segmentelevation myocardial infarction (26.7%), and most had evidence of multivessel CAD (66.7%). Prevalence of smoking, hypertension, diabetes mellitus, and firstdegree family history of CAD was higher in cases from the UK Biobank and local cohorts compared with participants in the UK Biobank control group (Table 1) . BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; HbA1c, glycohemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NSTEMI, non-ST-segment-elevation myocardial infarction; STEMI, ST-segmentelevation myocardial infarction; UKB, UK Biobank cohort; and WHR, waist-to-hip ratio.
*Age that CAD was first diagnosed (self-report) for the UK Biobank cases and age of recruitment for the UK Biobank controls. †Previous or current smoking for the UKB (smoking status at the time of event was not available). ‡First-degree family history of CAD: man, <55 y and woman, <65 y in the local cohort; any history in the UKB (age was not available). §In the local cohort, 9 of the 29 participants with available lipid profiles were on cholesterol-lowering medication at the moment of the measurement.
‖Cholesterol-lowering medication (statin, fibrate, or ezetimibe) at time of angiography.
Genetic Risk Score
UK Biobank
In the UK Biobank cohort, participants with EOCAD had a significantly higher GRS182 than controls (mean of 11.21 compared with mean of 10.88; P=3.21×10 −9 ). Mean GRS182 estimated from HRC and 1000 Genomes allele frequencies was similar to the control group (Table IV in the Data Supplement). Distribution of GRS182 in participants with EOCAD showed a right shift on visual inspection (Figure 1 ). An increase of 1 SD (0.52) in GRS182 corresponded to an OR of 1.84 (1.52-2.24) for EOCAD. The magnitude of effect remained similar after adjustment for age, sex, BMI, waist-to-hip ratio, smoking, hypertension, diabetes mellitus, and first-degree family history of heart disease, with an adjusted OR of 1.78 (1.45-2.17) for EOCAD. When the cohort was divided into quartiles of GRS182, there was a trend showing increasing risk by quartile (P=4.23×10 −8 ; Figure 2 ). The prevalence of individuals with an increase in EOCAD risk similar to what is observed in heterozygous FH (OR of 3.7 19 ) was estimated at 1 in 53.
Individuals with documented obstructive CAD regardless of age of onset also had a higher GRS182 than controls (mean of 11.11 compared with mean of 10.87; P=1.86×10 Among the individuals without EOCAD, individuals with GRS182 above a threshold that increased EOCAD risk 2-fold (GRS182 >11.57) had a higher proportion of hypertension, likely related to the effect on blood pressure of some of the variants included in the score (Table  II in the Data Supplement). We also found a higher proportion of first-degree family history of heart disease in the high GRS182 group. We did not observe a significant difference in BMI, waist-to-hip ratio, and smoking. There was no significant difference in clinical characteristics among the individuals with EOCAD (Table V in the Data Supplement).
Local Cohort
In the local cohort of individuals with EOCAD, mean GRS182 was significantly higher than in the UK Biobank cohort control group (11.23 versus 10.88; P=0.001) and corresponded to the 75th percentile of the latter distribution. Seven participants had an expected OR for EOCAD >2.0 compared with an average individual from the UK Biobank cohort control group (cases 1-7, Table 2; Figure 3 ; Table VI in the Data Supplement). There was a significant enrichment in high GRS182 in the local cohort (P=0.0003 and 0.0001 compared with UK Biobank cohort control group and general population estimated from HRC allele frequencies, respec- tively) using Fisher combined probability test (Table VI in the Data Supplement).
One individual (case 1) carried a high number of risk alleles (203, mean in UK Biobank cohort control group, 176) and had GRS182 above the 99.8th percentile of the expected distribution. This corresponded to an estimated OR of 6.09 (3.43-10.81) for EOCAD (from UK Biobank data; Figure 3 ). OR for CAD was estimated between 3.68 (3.46-3.92; from UK Biobank data) and 4.72 (3.86-5.78; from reported effect sizes in CARDIoGRAMplusC4D Consortium meta-analysis; Table VI in the Data Supplement). This female individual had an urgent angiography at 44 years of age in the context of a ST-segment-elevation myocardial infarction, which showed a 90% occlusion in the left anterior descending artery and a 50% occlusion in the circumflex artery. She was a smoker (≈30 pack-years) and had hypertension. There was no history of diabetes mellitus. Her sister and her mother had a myocardial infarction at 47 and 65 years of age, respectively. Her BMI was evaluated at 28.1 kg/m 2 . Low-density lipoprotein cholesterol was measured at 3.20 mmol/L, high-density lipoprotein cholesterol at 0.70 mmol/L, and triglycerides at 2.9 mmol/L (without treatment).
Of note, the difference in mean GRS182 between the cases in the local cohort and UK Biobank cohort control group, as well as the enrichment in high GRS182 compared with the UK Biobank cohort and HRC allele frequencies remained significant even after excluding case 1 (P=0.002, 0.003, and 0.002, respectively).
No rare mutation causing monogenic dyslipidemia or EOCAD was identified at whole-exome sequencing in the 7 participants with a substantial polygenic contribution.
DISCUSSION
Using a large cohort study as a reference, we found a significant enrichment for the presence of common risk variants associated with CAD in individuals with documented EOCAD. In a local cohort, we identified 7 individuals with a substantial genetically predicted increase in risk (OR >2). For one of the cases, the GRS was associated with an OR of 6.10 for EOCAD and 3.68 to 4.72 for CAD.
Our results are consistent with other studies reporting an association between GRSs and CAD. [20] [21] [22] [23] However, our approach is different because it identifies individuals at the high end of the distribution (top 10%), who have a significantly increased risk of CAD based on the presence of known common risk variants (ie, having an OR >2). Based on UK biobank cohort data, 1 in 53 individuals has a polygenic contribution that increases the risk to the same magnitude as FH, which surpasses the prevalence of FH (estimated at 1 in 256 19 ). The OR for CAD observed in the patient with the highest score (case 1) is comparable with what is expected for the combination of diabetes mellitus and hypertension (OR estimated at 4.5). 24 These results are consistent with a significant polygenic contribution in certain individuals with EOCAD, similar to what has recently been reported for FH. 25 This contribution is likely more important in individuals presenting with early manifestations, as suggested by observations from twin studies showing a stronger genetic effect when individuals are affected at younger ages. 26, 27 Of note, no rare mutation known to cause EOCAD was found at whole-exome sequencing in the 7 reported cases.
The score was associated with a gradual increase in risk for CAD and EOCAD. Because the GRS is mostly independent of known risk factors (most variants are not associated with CAD risk factors), such a tool could be used to better stratify a patient's risk and guide management. Adherence to a healthy lifestyle was reported to significantly decrease CAD risk in individuals considered at high genetic risk based on a similar GRS. 28 In the present study, we could not identify pro- tective factors in controls with high GRS182, but further studies, including diet and physical activity data, could be more informative. Moreover, in randomized trials of statin therapy for primary prevention, individuals at high genetic risk were shown to derive greater relative and absolute benefit. 29, 30 The score could also help to increase compliance in high-risk patients, as illustrated in a recent study showing a reduction in low-density lipoprotein cholesterol in patients randomized to receive the results of a GRS as part of the risk assessment strategy. 31 Further prospective studies in patients with EOCAD are warranted to demonstrate the potential benefits of adding a GRS to the clinical workup, both in terms of recurrence risk and identification of at-risk relatives.
Research is needed to identify the exact pathophysiological mechanism by which most of the reported common variants increase the risk. In the EOCAD cases from both cohorts, we observed a high frequency of traditional risk factors, notably for smoking but also hypertension, diabetes mellitus, and obesity. These risk factors likely contributed to the early manifestation of CAD, acting in combination with the genetic risk variants, as it was previously shown for FH. 32, 33 Our study has some limitations. First, strict criteria led to the inclusion of patients with a severe phenotype of EOCAD, corresponding to the bottom of the distribution in terms of age of onset, therefore, more likely to carry a genetic predisposition. We included individuals with late-onset CAD in the control group to obtain an estimate of the risk of EOCAD. Lateonset CAD, however, represented a minor fraction of the control group (2.1%), and any impact would lead to a more conservative estimate of the risk. Second, all individuals were of European descent; the use of the reported GRS might not apply to populations from other ethnic groups. Third, we chose to use a larger list of variants, including those associated with CAD at a false discovery rate of 5%. This strategy has previously been shown to yield a stronger association with prevalent and incident CAD than when considering only genome-wide significant variants. 34 Fourth, we could not estimate absolute risks because we did not have sufficient data on incident coronary outcomes. Fifth, information on traditional risk factors in the UK Biobank cohort did not include smoking level and blood lipids.
In conclusion, we show a significant polygenic contribution in individuals presenting with EOCAD, which could be more prevalent than FH. Determination of the polygenic risk component could, therefore, be included in the diagnostic workup of patients with EOCAD. This could provide answers to patients affected by such distressing events and would allow genetic screening of relatives. Further prospective studies are warranted to confirm the benefits of this approach.
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